Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Still’s disease is a rare rheumatic condition. This condition is characterized by biological and clinical symptoms such as high spiking fever, joint swelling, muscle pain, sore throat, increased number of white cells (leukocytes, especially neutrophils), and biological hepatitis. Treatment for still’s disease can be classified into 2 categories, namely symptomatic treatments and effective therapies. Symptomatic treatments can be initiated immediately, even when the diagnosis has not been established whereas, effective therapies are designed to treat the condition more efficiently to eradicate the symptoms of the disease.
According to a study published in The American Journal of Medicine, the treatment of still’s disease has been largely derived from retrospective data and case reports. While mild cases can be treated with NSAIDs (Nonsteroidal Anti-inflammatory Drugs), more than 80% of still’s disease patients need the use of corticosteroids and do not achieve remission. There is no such known risk factor that develops the Still’s disease, however, it is assumed that it is caused due to over activation of IL-1 (Interleukin-1) in the body.
The rising demand for specific new treatments and the emergence of drugs for still’s disease are expected to drive the still’s disease treatment market growth during the forecast period. For instance, as per the U.S. Food and Drug Administration (FDA), Canakinumab (Ilaris) can be indicated to all patients older than 2 years with Still's disease.
Still’s Disease Treatment Market - Impact of Coronavirus (Covid-19) Pandemic
Still’s disease treatment market is hugely affected due to the outbreak of COVID-19, as it is becoming difficult for researchers to conduct researches during this pandemic situation. People with rheumatic diseases such as Still's disease are more prone to getting infected with the coronavirus. Thus, majority of the vendors are concentrating on developing strategies to help patients with still’s disease to remain agile during the global disruptions due to COVID-19 pandemic. In addition, many government bodies across the globe are taking decisions such as new regulations to deal with the current crisis.
The all-inclusive version of the report will include the impact of COVID-19 and the probable changes in the future outlook of the industry, by taking into account the technological, social, political, and economical parameters.
The still’s disease treatment market is estimated to be valued at US$ 1,539.4 million in 2020 and is expected to rise at a CAGR of 4.49% during the forecast period (2020-2027).
Figure 1. Still’s Disease Treatment Market Share (%) Analysis, By Route of Administration, 2020
An increase in the number of mergers & acquisitions and drug launches is expected to propel growth of the still’s disease treatment market
Key players in the market are involved in mergers & acquisitions to develop advanced drugs and treatment, and launch them in the still’s disease treatment market. The drug launches in the industry is estimated to significantly boost the market growth and create lucrative growth opportunities in the overall market during the forecast period.
For instance, in July 2018, SOBI launched a third-line treatment, Kineret drug for the treatment of adult-onset still's disease (AOSD). This new therapy is indicated when the patient does not respond to Disease-modifying antirheumatic drugs (DMARDs) and corticosteroids, and fail to respond to methotrexate. The drug is currently available in the U.K. for Cryopyrin-associated periodic syndromes (CAPS) and rheumatoid arthritis (RA).
Furthermore, companies are adopting several strategies such as license agreements and partnerships to hold a strong position in the global industry. For instance, in July 2019, Aevi Genomic Medicine entered into a license agreement with AstraZeneca for phase II trials of MEDI2338, which is a fully human mAb (monoclonal antibody) that targets IL-18 (interleukin 18). The company has planned to initially develop MEDI2338 for AOSD (adult-onset Still's disease), which is a rare and orphan rheumatological disease with presently no approved biologic therapies in the U.S.
Still’s Disease Treatment Market - Restraints
Unavailability of specific therapeutics for still’s disease condition is considered to be one of the potential restraints affecting the market growth. For instance, the treatment for still’s disease is directed towards the use of anti-inflammatory drugs such as aspirin and other nonsteroidal drugs (NSAIDs). In some cases, cortisone medications such as prednisone are used to treat the condition. Other factors such as increasing number of generic therapeutics, product recalls, and patent expiration of licenses & various drugs are likely to hamper the market growth.
Still’s Disease Treatment Market Report Coverage
||Market Size in 2019:
||US$ 1,539.4 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 2,093.8 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Treatment: Tocilizumab, Canakinumab, Anakinra, Pain Management, Corticosteroids Therapy, Other.
- By Route of Administration: Injectable, Oral.
- By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies.
AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.
- Increasing prevalence of Still’s disease across the globe
- Increasing investments in research & development to develop novel treatment
|Restraints & Challenges:
- Introduction of generics and patent expiration of branded drugs
- Lack of healthcare budget in low- and middle-income countries
Still’s Disease Treatment Market – Regional Analysis
Europe region accounted for the largest share in the still’s disease treatment market in 2019, owing to the increasing focus of key players on research & development and European Commission (EC) approvals in the market. For instance, in April 2018, Swedish Orphan Biovitrum AB announced that Kineret (anakinra) is approved by the EC for the treatment of still’s disease. Kineret is indicated for adults, children, adolescents, and infants aged 8 months and above with at least 10kg bodyweight for the treatment of Still’s disease. This also includes AOSD and SJIA with active systemic features of moderate to high disease activity.
The U.S. market followed the same. In June 2020, the U.S. FDA approved Switzerland-based Novartis’s Ilaris injection for the treatment of active still’s disease. This approval also includes treatment for Adult-Onset Still’s Disease (AOSD). The Ilaris injection was formerly approved for SJIA (Systemic Juvenile Idiopathic Arthritis) in patients aged 2 years and above.
The Asia Pacific region is witnessing a promising growth in the global still’s disease treatment market, owing to initiatives taken by key players and approvals for the treatment of adult still’s disease. For instance, in May 2019, Chugai Pharmaceutical Co., Ltd., a subsidiary of F. Hoffmann-La Roche Ltd. received expanded approval from the MHLA (Ministry of Health Labor and Welfare) in Japan for Actemra (tocilizumab) for the treatment of adult Still’s disease.
Figure 2. Still’s Disease Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Still’s Disease Treatment Market - Competitive Landscape
Key players operating in the Still’s disease treatment market include AB2 Bio Ltd., F. Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Vintage Labs, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Zydus Cadila, Amneal Pharmaceuticals LLC, Dr Reddy's Laboratories Ltd., and Fresenius Kabi AG.